

Date: 09.08.2024

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 09th August, 2024

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. 09th August, 2024, inter alia, considered and approved followings:

1. Unaudited Financial Results along with Limited Review Report for the quarter ended on 30th June, 2024.
2. Appointment of Mr. Rohit J Shah (DIN: 06885402) as an Additional Director (Non – Executive, Independent Director) of the Company as recommended by Nomination and Remuneration Committee for the period of 5 years with effect from 09th August, 2024 subject to approval of the Shareholders at the ensuing general meeting.
3. Appointment of Mrs. Rangoli S Gada (DIN:10109783) as an Additional Director (Non – Executive, Independent Director) of the Company as recommended by Nomination and Remuneration Committee for the period of 5 years with effect from 09th August, 2024 subject to approval of the Shareholders at the ensuing general meeting.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in

The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 with regard to change in Directors and Key Managerial Personnel are enclosed herewith Annexure.

The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 01:20 p.m.

Kindly take the same on your record.

Thanking you,

Yours truly,
For Link Pharma Chem Limited

Khushbu Patel
Company Secretary & Compliance officer
Membership No.: A65182

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LIMITED
CIN : L24230GJ1984PLC007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30th June 2024	31st March, 2024	30th June 2023	31st March 2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	884.63	803.24	787.63	2,989.77
	Other income	27.16	(1.05)	30.66	64.03
	Total Income (A)	911.80	802.19	818.29	3,053.80
2	Expenses:				
	Cost of materials consumed	499.56	473.76	210.21	1,436.95
	Changes in inventories of finished goods and work-in-progress	7.63	(95.14)	345.79	231.14
	Employee benefits expense	130.81	141.91	133.21	551.61
	Finance costs	22.03	19.48	22.87	87.20
	Depreciation and amortization expense	23.54	24.92	25.76	103.42
	Other Expenses	192.19	190.71	194.67	835.05
	Total expenses (B)	875.76	755.64	932.50	3,245.37
3	(Loss)/Profit before tax (C) = (A-B)	36.03	46.55	(114.21)	(191.57)
4	Tax expense:				
	(1) Current tax	-	-	-	-
	(2) Short/(Excess) Provision of tax relating to earlier Year	-	-	-	0.63
	(3) Deferred tax	6.39	20.55	(31.92)	(55.92)
	Total tax expense (D)	6.39	20.55	(31.92)	(55.29)
5	(Loss)/Profit for the year/period (E) = (C-D)	29.64	26.00	(82.29)	(136.29)
6	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Net fair value gain on equity instruments through Other Comprehensive Income	0.16	0.04	0.15	0.38
	Remeasurement (loss) / gain of the defined benefit plan	1.02	15.34	(3.75)	4.09
	Income tax effect on above	(0.32)	(4.07)	0.94	(1.22)
	Total other comprehensive income for the year/period, net of tax (F)	0.86	11.31	(2.67)	3.25
7	Total comprehensive income for the year/period (Net of Tax) (E+F)	30.50	37.31	(84.96)	(133.04)
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06
9	Other Equity				926.81
10	Earnings per equity share (FV of Rs. 10) (Rs.)				
	Basic and Diluted	0.67	0.59	(1.85)	(3.07)



REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

Notes:

- 1 The above financial results for the quarter ended on June 30th, 2024 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 09th, 2024.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 - 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

Particulars	Quarter ended			Year ended
	30th June 2024	31st March, 2024	30th June 2023	31st March 2024
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Other income (A)	27.16	(1.05)	30.66	64.03
Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	23.23	(10.07)	26.43	49.21
Adjusted Other Income (A-B)	3.93	9.02	4.23	14.82

- 4 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the relevant financial year.

Date : August 9th, 2024
Place : Vadodara



For Link Pharma Chem Limited

Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :


Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Link Pharma Chem Limited

1. We have reviewed the accompanying Statement of Unaudited Financial results of **Link Pharma Chem Limited** ("the Company") for the quarter ended 30th June, 2024 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036


Pareen Shah

Partner
Membership No. 125011
Place: Vadodara
Date: 9th August, 2024
UDIN: 24125011BKERBE6927



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

Annexure

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Independent Directors

Sr. No.	Disclosure Requirement	Details	Details
01.	Reason for change, viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Rohit J Shah as an Additional Director (Non – Executive, Independent Director) of the Company, subject to approval of the Shareholders.	Appointment of Mrs. Rangoli S Gada as an Additional Director (Non – Executive, Independent Director) of the Company, subject to approval of the Shareholders.
02.	Date of appointment / cessation (as applicable) & term of appointment	09 th August, 2024 Appointment as an Additional Director (Category –Independent Director) of the Company for the period of 5 years with effect from 09 th August, 2024, subject to approval of shareholders of the Company at the ensuing General Meeting.	09 th August, 2024 Appointment as an Additional Director (Category- Independent Director) for the period of 5 years of the Company with effect from 09 th August, 2024, subject to approval of shareholders of the Company at the ensuing General Meeting.
03.	Brief profile	Mr. Rohit J. Shah possess two professional qualifications namely Cost and Management Accountant and Chartered Accountant having rich professional experience of project finance, cost control and cost reduction, taxation planning, internal control management, internal audit and general management of the Company.	Mrs. Rangoli S Gada is a Practicing Chartered Accountant and having experience of handling Statutory audit, Tax audit, Internal audit, Advisory on taxation of individual, firm LLP, Handling Assessment proceedings, Representation & Litigation (including independently handling appeals at ITAT level, Restructuring of partnership firms and LLP, Tax planning of HNIs, Handling investigation matter of income tax, ERP system etc.
04.	Disclosure of relationships between Directors (in case of appointment of a director)	Mr. Rohit J Shah is not related to any of the Promoters, Members of the Promoter Group and Directors of the Company and is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.	Mrs. Rangoli S Gada is not related to any of the Promoters, Members of the Promoter Group and Directors of the Company and is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in